In the News

« Back

PhotoniCare Announces FDA Clearance for First-In-Class Technology for Imaging the Ear

TOMi Scope [OtoSight Middle Ear Scope] allows healthcare providers, for the first time ever, to non-invasively view fluid directly in the middle ear, even in the presence of wax build-up

Champaign, Ill. – Jan. 6, 2020 – PhotoniCare, Inc., a company dedicated to revolutionizing healthcare by providing healthcare providers with better diagnostic tools, today announced that the U.S. Food & Drug Administration (FDA) has granted 510(k) clearance for its TOMi™ Scope [OtoSight Middle Ear Scope] for non-invasive imaging of the middle ear. Using optical coherence tomography (OCT) high resolution depth imaging, TOMi Scope [OtoSight Middle Ear Scope] helps to determine the presence or absence of fluid in the middle ear and to characterize the fluid type.

“Current tools can only provide a view of the surface of the eardrum, forcing healthcare providers to make an assessment with very limited information, or to employ invasive surgical procedures to accurately identify middle ear pathologies,” said Diego Preciado, M.D., Ph.D. of the Children’s National Hospital in Washington, D.C., a lead investigator for clinical studies of the device. “TOMi Scope’s [OtoSight Middle Ear Scope] advanced light-based technology could dramatically alter the way children with ear problems are evaluated, enhancing our ability to inform optimal treatments.”

Middle ear infections are the leading cause of hearing loss, surgery and antibiotic use, especially in children. Affecting more than 80% of children, they are misdiagnosed up to 50% of the time using the current gold standard, examination via otoscope.[i] Children can suffer from recurring ear infections for six to 12 months before they are referred to an ENT specialist, and are often prescribed increasingly potent antibiotics during this time. More than one million tube surgeries are performed in the U.S. alone every year.

“Clinicians seeking to be more accurate and confident in their assessment of middle ear fluid and fluid type will find this new technology using light wave detection very helpful,” said Michael Pichichero, M.D., Director of the Rochester General Hospital Research Institute and Research Professor at the Rochester Institute of Technology in New York. “The fact that it works well even in the presence of significant wax build-up is of great value. Wax continues to be a huge problem in middle ear diagnosis.”

“At PhotoniCare we set out to solve the massive problem of frequent misdiagnosis of middle ear infections, and the overuse of antibiotics and referrals to surgery in children that result,” added PhotoniCare co-founder & CEO Ryan Shelton. “We thank the FDA for clearing our TOMi Scope [OtoSight Middle Ear Scope] under a new product code unique to our technology, and look forward to bringing this innovation to doctors and patients very soon.”

PhotoniCare expects to immediately launch the TOMi Scope [OtoSight Middle Ear Scope] in a limited release in select U.S. geographies, with a full national launch later in 2020.

About PhotoniCare

Founded in 2013, PhotoniCare’s mission is to revolutionize healthcare by providing healthcare providers with better diagnostic tools, starting with the TOMi Scope™ [OtoSight Middle Ear Scope], the first and only otoscope to provide non-invasive imaging of the middle ear using a novel application of Optical Coherence Tomography (OCT) to directly visualize and characterize fluid in the middle ear, a necessity for the diagnosis of  middle ear infections. PhotoniCare has developed a patented imaging platform technology that provides growth opportunities beyond otology (study of the ear). Peer-reviewed studies show that the same handheld OCT technology can be used to image other areas, such as the anterior and posterior segments of the eye, the skin, and in the mouth.

PhotoniCare has been recognized by numerous organizations, winning the 2018 MedTech Innovator Execution Award and the 2018 AdvaMed Accel Virginia Shimer Rybski Memorial Award. The company was also a member of the 2016 Dreamit Ventures accelerator program and recently took first place at the 7th Annual Insight Product Development 2019 HealthTECH Startup Competition. PhotoniCare has received more than $4 million in support from the National Institutes of Health, most recently a Phase SBIR I award for work in artificial intelligence. In 2015, PhotoniCare was the winner of a grant from the National Capital Consortium for Pediatric Device Innovation (NCC-PDI), an FDA-funded consortium led by Children’s National Hospital.


Media Contact:
Brad Perriello

Investor Contact:
Ryan Shelton

[i] Pichichero, Michael E., Poole, Michael D. Assessing Diagnostic Accuracy and Tympanocentesis Skills in the Management of Otitis Media. Arch. Pediatr. Adolesc. Med. 2001. 155(10):1137-1142. doi:10.1001/archpedi.155.10.1137

Related News

  • Dr Novak and Patient using OtoSight

    PhotoniCare Announces Rebranding of First-in-Class Technology for Imaging the Middle Ear, Now called OtoSight Middle Ear Scope

    Champaign, IL – PhotoniCare, Inc., a company dedicated to revolutionizing healthcare… Read More

  • PhotoniCare Appoints Former Welch Allyn CEO Steve Meyer to Advisory Board.

    Reports show that each year over 9-million children are diagnosed… Read More

  • PhotoniCare CEO, Ryan Shelton, Wins NWA Pitch Competition

    The Northwest Arkansas Tech Summit declared Ryan Shelton, CEO and… Read More